These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38737553)

  • 21. Initial growth deceleration during GnRH analogue therapy for precocious puberty.
    Mouat F; Hofman PL; Jefferies C; Gunn AJ; Cutfield WS
    Clin Endocrinol (Oxf); 2009 May; 70(5):751-6. PubMed ID: 19178517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
    Li WJ; Gong CX; Guo MJ; Xing J; Li T; Song WH; Luo XP; Wu D; Liang JP; Cao BY; Gu Y; Su C; Liang XJ; Liu M; Wang R; Li FT
    Chin Med J (Engl); 2015 May; 128(10):1314-20. PubMed ID: 25963350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
    Mericq G MV; Youlton R R; Willshaw Z ME
    Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
    Shim YS; Lim KI; Lee HS; Hwang JS
    PLoS One; 2020; 15(12):e0243212. PubMed ID: 33301485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
    Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
    Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.
    Nam HK; Kim HR; Rhie YJ; Lee KH
    J Korean Med Sci; 2017 Mar; 32(3):475-479. PubMed ID: 28145651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
    Hagen CP; Sørensen K; Anderson RA; Juul A
    Fertil Steril; 2012 Nov; 98(5):1326-30. PubMed ID: 22901847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Levels of Thyroid Stimulating Hormone and Luteinizing Hormone Are Decreased in Girls with Central Precocious Puberty after 12-Month GnRH Agonist Treatment.
    Kim YJ; Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    Tohoku J Exp Med; 2020 Nov; 252(3):193-197. PubMed ID: 33087637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy.
    Witchel SF; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1353-6. PubMed ID: 8636332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty.
    Trujillo MV; Lee PA; Reifschneider K; Backeljauw PF; Dragnic S; Van Komen S; Yu J; Klein KO
    J Pediatr Endocrinol Metab; 2023 Mar; 36(3):299-308. PubMed ID: 36473097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum leptin levels in patients with progressive central precocious puberty.
    Heger S; Partsch CJ; Peter M; Blum WF; Kiess W; Sippell WG
    Pediatr Res; 1999 Jul; 46(1):71-5. PubMed ID: 10400137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
    Lanes R; Gunczler P
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years.
    Vargas Trujillo M; Dragnic S; Aldridge P; Klein KO
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):733-739. PubMed ID: 33856747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Near final height after GnRH agonist treatment in central precocious puberty.
    Micillo M; Salerno M; Officioso A; Perna E; Gasparini N; Pisaturo L; Di Maio S
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():787-90. PubMed ID: 10969922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.